Therapeutic Digest

Mental Health Revolution

February 15, 2020

Within the mental health category, progress is being driven by FDA initiatives to encourage novel submissions, the engagement of pharmaceutical companies to assess biomarkers through development and approval, as well as the academic research conducted by the consortia of psychiatric research. New technologies are identifying new disease characteristics and by leveraging FDA breakthrough therapy and fast track drug designations, the pipeline provides a promising path for novel drug applications in areas of unmet or underserved medical need.

Post a Comment

You must be logged in to post a Comment.

FEEDBACK